Abstract Objective To study the association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy (SMA). Methods A total of 45 children with SMA were enrolled. Multiplex ligation-dependent probe amplifcation was used to measure the gene copy numbers of SMN1 and SMN2. The association of copy number of SMN1 and SMN2 with clinical phenotypes was analyzed. Results Of the 45 children with SMA, 42 (93%) had a homozygous deletion of SMN1 exons 7 and 8, and 3 (7%) had a deletion of SMN1 exon 7 alone. No association was found between SMA clinical types and the deletion types of SMN1 exons 7 and 8 (P > 0.05). There was a signifcant difference in the distribution of SMN2 gene copy numbers between the children with SMA and the healthy children (P < 0.05). The children with SMA usually had two or three copies of SMN2 gene, while the healthy children usually had one or two copies of SMN2 gene. There was a significant difference in the distribution of SMN2 copy numbers among the children with different SMA clinical types (P < 0.05). The children with two copies of SMN2 gene had a signifcantly lower age of onset than those with three or four copies. Most of the children with type I SMA had two or three copies of SMN2 gene. Most of the children with type Ⅱ SMA had three copies of SMN2 gene. Most of the children with type Ⅲ SMA had three or four copies of SMN2 gene. Children with a higher copy number of SMN2 gene tended to have an older age of onset and better motor function and clinical outcome, and there was a signifcant association between SMN2 gene copy number and clinical outcome (P < 0.05). Conclusions The SMN2 gene can reduce the severity of SMA via the dosage compensation effect. SMN2 copy number is associated with the phenotype of SMA, and therefore, it can be used to predict disease severity.
ZHANG Yin-Hong,ZHANG Yun-Qian,ZHU Bao-Sheng et al. Association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy[J]. CJCP, 2019, 21(3): 239-243.
ZHANG Yin-Hong,ZHANG Yun-Qian,ZHU Bao-Sheng et al. Association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy[J]. CJCP, 2019, 21(3): 239-243.
Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy[J]. Am J Med Genet A, 2010, 152A(7):1608-1616.
[2]
Sheng-Yuan Z, Xiong F, Chen YJ, et al. Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population[J]. Eur J Hum Genet, 2010, 18(9):978-984.
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy-a literature review[J]. Orphanet J Rare Dis, 2017, 12(1):124.
[5]
Faravelli I, Nizzardo M, Comi GP, et al. Spinal muscular atrophy--recent therapeutic advances for an old challenge[J]. Nat Rev Neurol, 2015, 11(6):351-359.
[6]
Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy:diagnosis and management in a new therapeutic era[J]. Muscle Nerve, 2015, 51(2):157-167.
[7]
Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy[J]. Ann Neurol, 2017, 81(3):355-368.
Munsat TL, Davies KE. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany)[J]. Neuromuscul Disord, 1992, 2(5-6):423-428.
[10]
Haché M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy:nusinersen clinical trial experience[J]. J Child Neurol, 2016, 31(7):899-906.
[11]
Pechmann A, Langer T, Wider S, et al. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1[J]. Eur J Paediatr Neurol, 2018, 22(1):122-127.
[12]
He J, Zhang QJ, Lin QF, et al. Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy[J]. Gene, 2013, 518(2):325-329.
[13]
Fang P, Li L, Zeng J, et al. Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls[J]. BMC Musculoskelet Disord, 2015, 16(1):11.
Qu YJ, Ge XS, Bai JL, et al. Association of copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein gene with the natural history in a Chinese spinal muscular atrophy cohort[J]. J Child Neurol, 2015, 30(4):429-436.
[17]
Butchbach ME. Copy number variations in the survival motor neuron genes:implications for spinal muscular atrophy and other neurodegenerative diseases[J]. Front Mol Biosci, 2016, 3:7.
Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening[J]. J Neuromuscul Dis, 2018, 5(2):145-158.
[20]
Prior TW, Swoboda KJ, Scott HD, et al. Homozygous SMN1 deletions in unaffected family members and modifcation of the phenotype by SMN2[J]. Am J Med Genet A, 2004, 130A(3):307-310.
[21]
Ahn EJ, Yum MS, Kim EH, et al. Genotype-phenotype correlation of SMN1 and NAIP deletions in Korean patients with spinal muscular atrophy[J]. J Clin Neurol, 2017, 13(1):27-31.
[22]
Nishio H. PLS3 expression and SMA phenotype:a commentary on correlation of PLS3 expression with disease severity in children with spinal muscular atrophy[J]. J Hum Genet, 2014, 59(2):64-65.
[23]
Strathmann EA, Peters M, Hosseinibarkooie S, et al. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice[J]. PLoS One, 2018, 13(9):e0203398.
[24]
Hosseinibarkooie S, Peters M, Torres-Benito L, et al. The power of human protective modifiers:PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype[J]. Am J Hum Genet, 2016, 99(3):647-665.
[25]
Riessland M, Kaczmarek A, Schneider S, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis[J]. Am J Hum Genet, 2017, 100(2):297-315.
